Works matching IS 00070920 AND DT 2019 AND VI 120 AND IP 3
Results: 12
Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours.
- Published in:
- 2019
- By:
- Publication type:
- journal article
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistance.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Kidney stones and the risk of renal cell carcinoma and upper tract urothelial carcinoma: the Netherlands Cohort Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Personal radio use and cancer risks among 48,518 British police officers and staff from the Airwave Health Monitoring Study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
HPV, tumour metabolism and novel target identification in head and neck squamous cell carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Interferon-alpha promotes immunosuppression through IFNAR1/STAT1 signalling in head and neck squamous cell carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Co-targeting EGFR and IKKβ/NF-κB signalling pathways in head and neck squamous cell carcinoma: a potential novel therapy for head and neck squamous cell cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer.
- Published in:
- 2019
- By:
- Publication type:
- journal article